Is capmatinib suitable for advanced non-small cell lung cancer?

Capmatinib (Capmatinib) is a highly selective MET inhibitor, specifically used to treat patients with MET exon 14 skipping mutations (METex14 skipping mutation) non-small cell lung cancer (NSCLC) patients. The incidence of this type of mutation in lung cancer is about 3-4%, and it is especially common in elderly patients and patients with lung adenosquamous carcinoma. For these patients, capmatinib can significantly inhibit the growth and metastasis of tumor cells by blocking the MET signaling pathway, making it an important means of precision treatment.

Capmatinib has shown good efficacy in the treatment of advanced non-small cell lung cancer. According toGEOMETRY Mono-1clinical trial data show capmatinib’s objective response rate ( ORR) can reach about 68%, and for patients who have received previous treatment, ORR can also be maintained at around 40%. Most patients can observe a reduction in tumor size after receiving treatment, and some may even achieve partial or complete remission.

In addition, capmatinib also shows certain activity in controlling distant lesions such as brain metastases, which is another advantage in the treatment of advanced NSCLC. Because METex14 mutated tumors progress rapidly and have limited effectiveness with traditional chemotherapy or immunotherapy, capmatinib is a more targeted and efficient treatment option for advanced patients with clear such gene mutations.

In summary, capmatinib is indeed suitable for the treatment of patients with advanced non-small cell lung cancer carrying METex14 skipping mutations. In practical applications, the mutation status needs to be clarified through genetic testing before deciding whether to use capmatinib. In addition, patients need to closely monitor drug side effects, such as peripheral edema, nausea, liver function abnormalities, etc. during treatment to ensure safe and effective use of the drug. Individualized medication and regular follow-up remain key.

Reference materials:https://www.drugs.com/